PPIs: Good or Bad? 1. Basics of PPIs. Gastric Acid Basics. Outline. Gastric Acid Basics. Proton Pump Inhibitors (PPI)
|
|
- Angelina Howard
- 5 years ago
- Views:
Transcription
1 Outline Quick basics on Proton Pump Inhibitors (PPIs) PPIs: Good or Bad? What are potential risks of PPI therapy? How to approach your patients American Gastroenterology Association (AGA) recommendations Gastric Acid Basics 1. Basics of PPIs Gastric acid is good Digestion especially protein Absorption nutrients including calcium and iron Gastric acid can be a problem GERD Symptomatic heartburn Erosive Esophagitis/Barrett s Peptic stricture Peptic ulcer disease Dyspepsia GI bleed Gastric outlet obstruction Hypersecretory syndromes Zollinger-Ellison Gastric Acid Basics Treatments before PPI included Antacids H2B blockers: Cimetidine was the first in 1970s Short duration of action Tachyphlaxis Surgical Partial gastrectomy (Bilroth 1 and 2) Vagotomy Pyloroplasty Proton Pump Inhibitors (PPI) Introduction 1988 Omeprazole first on market 2000 Esomeprazole Now novel PPI in development Concentrate in parietal cells bind H/K/ATPase IRREVERSIBLY inhibition up to 36 hrs before acid pumps regenerate High metabolized by CYP 1
2 Current PPIs: All are pretty much the same Increased usage Increased problems? Pantoprazole 40mg: Tecta, Pantoloc Rabeprazole 20mg: Pariet Lansoprazole 30mg: Prevacid Omeprazole 20-60mg: Losec Esomeprazole 20-40mg: Nexium (Available OTC) Superior to Omeprazole/Lansoprazole in healing of erosive esophagitis Dexlansoprazole : Dexilant Dual action PPI (immediate and long acting) in once daily dosing Things that have made the headlines 2. What are the potential risks of chronic PPI? Kidney disease: increased CKD, AIN, AKI Dementia Bone fracture MI: decreased Clopidogrel effect due to CYP inhibition Infection: Bacterial overgrowth, Non typhoid Salmonella/Campylobacter, Spontaneous bacterial peritonitis, C Difficile, Community Acquired Pneumonia Micronutrient deficiency: calcium, iron, magnesium, B12 Malignancy: related to increased gastrin What is big challenge in interpreting the headlines (and fake news in general ) What is the quality of the data in terms of risks? Epidemiologic data: large population studies retrospective Residual confounders Randomized data is lacking helps balance confounders as we cannot always correct for them Kidney International (2008) 73,
3 COGENT: Clopidogrel with or without Omeprazole in Coronary Artery Disease COGENT subset: PPI reduces GIB in patients with Dual antiplatelet regardless of ASA dose without change in CV events N Engl J Med Nov 11;363(20): What is the quality of the data in terms of risks? J Am Coll Cardiol Apr 12;67(14): What is the quality of the data of benefit with PPI? Advice 1 Patients with GERD and acid-related complications (i.e., erosive esophagitis or peptic stricture) should take a PPI for short-term healing and for long-term symptom control. 3. AGA Best practice recommendations: What to do with and tell your patients Rationale: PPIs are highly effective in healing esophagitis and for GERD symptom control, and this benefit is likely to outweigh PPI-related risks. There is no evidence for or against PPIs in asymptomatic patients with healed esophagitis or for PPIs beyond 12 months. 3
4 Advice 2 Patients with uncomplicated GERD who respond to short-term PPIs should subsequently attempt to stop or reduce them. Patients who cannot reduce PPIs should consider ambulatory esophageal ph/impedance monitoring before committing to lifelong PPIs to help distinguish GERD from a functional syndrome. The best candidates for this strategy may be patients with predominantly atypical symptoms or those who lack an obvious predisposition to GERD (eg, central obesity, large hiatal hernia). Rationale: Short-term PPIs are highly effective for uncomplicated GERD. Most patients with uncomplicated GERD respond to short-term PPIs and are subsequently able to reduce PPIs to less than daily dosing. Because patients who cannot reduce PPIs face lifelong therapy, we would consider testing for an acid-related disorder in this situation. However, there is no high-quality evidence on which to base this recommendation. Advice 3 Patients with Barrett s esophagus and symptomatic GERD should take a long-term PPI. Rationale: PPIs have a clear symptomatic benefit and a possible benefit in slowing progression of Barrett s. There is likely to be a net benefit for long-term PPIs in these patients. Advice 4 Asymptomatic patients with Barrett s esophagus should consider a long-term PPI. Rationale: The evidence that PPIs slow progression of Barrett s is low in quality but the evidence of PPI adverse effects is also low in quality. Because there is no high quality evidence on either side of this question, this is a weak recommendation and this decision should be individualized with patients. Advice 5 Patients at high risk for ulcer-related bleeding from NSAIDs should take a PPI if they continue to take NSAIDs. Rationale: PPIs are highly effective in preventing ulcer-related bleeding in appropriately selected patients who take NSAIDs, and this benefit is likely to outweigh PPI-related risks. Advice 6 The dose of long-term PPIs should be periodically reevaluated so that the lowest effective PPI dose can be prescribed to manage the condition. Rationale: Long-term PPI users often receive PPIs at doses higher than necessary to manage their condition. Since PPI reduction is often successful, it is logical to periodically reevaluate PPI dosing so that the minimum necessary dose is prescribed. Advice 7 Long-term PPI users should not routinely use probiotics to prevent infection. Rationale: There is no evidence for or against probiotics to prevent infections in long-term users of PPIs. 4
5 Advice 8 Long-term PPI users should not routinely raise their intake of calcium, vitamin B12 or magnesium beyond the Recommended Dietary Allowance (RDA). Rationale: There is no evidence for or against use of vitamins or supplements beyond the RDA in long-term users of PPIs. Many adults fall below the RDA in several vitamins or minerals and, in these adults, it is reasonable to raise intake to meet the RDA regardless of PPI use. Advice 9 Long-term PPI users should not routinely screen or monitor bone mineral density, serum creatinine, magnesium, or vitamin B12. Rationale: There is no evidence for or against dedicated testing for patients taking long-term PPIs. Such screening (eg, for iron or vitamin B12 deficiency) can be offered but is of no proven benefit. Advice 10 Specific PPI formulations should not be selected based on potential risks. Rationale: There is no convincing evidence to rank PPI formulations by risk. Who to refer for evaluation? Barrett s screening Chronic GERD > 5 years and 2 of: Age > 50 Male Tobacco usage Central obesity Caucasian Dysphagia Refractory GERD You can consider ordering 24 hr ph with impedance +/- manometry Check Celiac serology and trial Lactose free Functional GERD similar to IBS Am J Gastroenterol Jan;111(1):30-50; What to tell your patient Pearls GERD Complicated (Esophagitis, Stricture) Uncomplicated Short term PPI Identify the indication Strengthens argument for or against long term usage Reassurance and monitoring Barretts GERD no GERD Consider PPI Reassess dosing and duration Trials of discontinuation Rebound reflux: taper off NSAIDS Long term Short term No PPI Assess indications for endoscopy ASA Plavix Monotherapy PPI No PPI (unless history of PUD, GIB or GERD) Continue to assess lowest dose and duration 5
Appropriate Use of Proton Pump Inhibitors (PPIs) Anderson Mabour, Pharm.D., BCPS Clinical Pharmacy Specialist
Appropriate Use of Proton Pump Inhibitors (PPIs) Anderson Mabour, Pharm.D., BCPS Clinical Pharmacy Specialist Disclosures I have no actual or potential conflicts of interest to report in relation to this
More informationProton Pump Inhibitors (PPIs) (Sherwood Employer Group)
Proton Pump Inhibitors (PPIs) (Sherwood Employer Group) BCBSKS will review Prior Authorization requests Prior Authorization Form: https://www.bcbsks.com/customerservice/forms/pdf/priorauth-6058ks-st-ippi.pdf
More informationProton Pump Inhibitors Drug Class Prior Authorization Protocol
Proton Pump Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medi-Cal P&T Approval Date: November 15, 2017 Effective Date: January 1, 2018 This policy has been developed through review
More informationA C A D E M I C D E TA I L I N G C H O O S I N G W I S E LY C O N F E R E N C E O C T 2 1, PA M M C L E A N - V E Y S E Y B S C P H A R M D R
PPI DEPRESCRIBING Canadian Deprescribing Network (CaDeN) goals are to: Reduce harm by raising awareness and cutting risky prescriptions for seniors by 50% by 2020. Promote health by ensuring access to
More informationDrug Class Monograph
Drug Class Monograph Class: Proton Pump Inhibitors Drugs: Aciphex Sprinkle (rabeprazole), Dexilant (dexlansoprazole), Lansoprazole, Nexium (esomeprazole capsule, esomeprazole granules), Omeprazole, Pantoprazole,
More informationProton Pump Inhibitors. Description. Section: Prescription Drugs Effective Date: July 1, 2014
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.09.01 Subject: Proton Pump Inhibitors Page: 1 of 7 Last Review Date: June 12, 2014 Proton Pump Inhibitors
More informationRpts. GENERAL General Schedule (Code GE) Program Prescriber type: Dental Medical Practitioners Nurse practitioners Optometrists Midwives
Esomeprazole 20mg Name, Restriction, Manner of esomeprazole 20 mg enteric tablet, 30 (8886Q) (029W) Gastric ulcer Peptic ulcer Treatment Phase: Initial treatment The therapy must be for initial treatment
More informationProton Pump Inhibitors
Market DC Proton Pump Inhibitors Override(s) Prior Authorization Quantity Limit** Approval Duration Preferred PPI: No Prior Authorization required Preferred PPI quantity override: Lifetime Non-Preferred
More informationGASTROINTESTINAL AND ANTIEMETIC DRUGS. Submitted by: Shaema M. Ali
GASTROINTESTINAL AND ANTIEMETIC DRUGS Submitted by: Shaema M. Ali GASTROINTESTINAL AND ANTIEMETIC DRUGS by: Shaema M. Ali There are four common medical conditions involving the GI system 1) peptic ulcers
More informationYou May Be at Risk. You are currently taking a proton-pump inhibitor (PPI): Dexlansoprazole (Dexilant ) Pantoprazole (Pantoloc, Panto IV )
You May Be at Risk. You are currently taking a proton-pump inhibitor (PPI): Dexlansoprazole (Dexilant ) Esomeprazole (Nexium ) Omeprazole (Losec, Olex ) Pantoprazole (Pantoloc, Panto IV ) Pantoprazole
More informationProton Pump Inhibitors. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.01 Subject: Proton Pump Inhibitors Page: 1 of 6 Last Review Date: June 24, 2015 Proton Pump Inhibitors
More informationYou May Be at Risk. You are currently taking a proton pump inhibitor (PPI):
PPI You are currently taking a proton pump inhibitor (PPI): Dexlansoprazole (Dexilant ) Esomeprazole (Nexium ) Omeprazole (Losec, Olex ) Lansoprazole (Prevacid, Prevacid Fast Tab ) Pantoprazole sodium
More informationDisclosures. Proton Pump Inhibitors Deprescribing? Deprescribing PPI Objectives. Deprescribing. Proton Pump Inhibitors (PPI) 5/28/2018.
Proton Pump Inhibitors Deprescribing? None Disclosures Chad Burski, MD Assistant Professor of Medicine UAB Gastroenterology Deprescribing PPI Objectives AR Why? Who? How? The mechanism of action of Proton
More informationGERD DIAGNOSIS & TREATMENT DISCLOSURES 4/18/2018
GERD DIAGNOSIS & TREATMENT Subhash Chandra MBBS Assistant Professor CHI Health Clinic Gastroenterology Creighton University, School of Medicine April 28, 2018 DISCLOSURES None 1 OBJECTIVES Review update
More informationPeptic ulcer disease Disorders of the esophagus
Peptic ulcer disease Disorders of the esophagus Peptic ulcer disease Burning epigastric pain Exacerbated by fasting Improved with meals Ulcer: disruption of mucosal integrity >5 mm in size, with depth
More informationDeveloping Evidence-Based Best Practices for the Prescribing and Use of Proton Pump Inhibitors in Canada
Developing Evidence-Based Best Practices for the Prescribing and Use of Proton Pump Inhibitors in Canada Presented by: Sumeet R. Singh, COMPUS April 4, 2006 Background COMPUS Objective: To identify and
More informationRefractory GERD. Kenneth R. DeVault, MD, FACG President American College of Gastroenterology Chair Department of Medicine Mayo Clinic Florida
Refractory GERD Kenneth R. DeVault, MD, FACG President American College of Gastroenterology Chair Department of Medicine Mayo Clinic Florida Objectives Define the terminology associated with refractory
More informationPRESCRIBING SUPPORT TEAM AUDIT: PROTON PUMP INHIBITOR PRESCRIBING REVIEW
PRESCRIBING SUPPORT TEAM AUDIT: PROTON PUMP INHIBITOR PRESCRIBING REVIEW DATE OF AUTHORISATION: AUTHORISING GP: PRESCRIBING SUPPORT TECHNICIAN: SUMMARY Dyspepsia refers to a broad range of symptoms related
More informationProton Pump Inhibitors:
Proton Pump Inhibitors: How bad could they be? Andrea Flanagan, Pharm.D. Iowa City VA Medical Center PGY-1 Pharmacy Resident Objectives for Pharmacists At the end of this presentation PHARMACISTS should
More informationHeartburn, also referred to acid reflux, happens when stomach acid flows back (refluxes) into your esophagus.
WHILE almost everyone experiences mild heartburn from time to time and many individuals have some antacids or another medication on hand for its relief, talk to your doctor, if you have heartburn more
More informationPolicy Evaluation: Proton Pump Inhibitors (PPIs)
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationOmeprazole 10mg. Name, Restriction, Manner of administration and form OMEPRAZOLE omeprazole 10 mg enteric tablet, 30 (8332M) Max. Qty.
Omeprazole 10mg Name, Restriction, Manner of administration and form omeprazole 10 mg enteric tablet, 30 (8332M) Gastro-oesophageal reflux disease Name, Restriction, Manner of administration and form omeprazole
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.CPA.209 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy for important
More informationPharmacy Coverage Guidelines are subject to change as new information becomes available.
PROTON PUMP INHIBITORS, NON-PREFERRED FORMS: ACIPHEX (rabeprazole sodium EC) oral tablet ACIPHEX SPRINKLE (rabeprazole sodium DR) oral capsule ESOMEPRAZOLE STRONTIUM (esomeprazole strontium DR) oral capsule
More informationProton Pump Inhibitor De-prescribing Guidance
Amendment History Proton Pump Inhibitor De-prescribing Guidance VERSION DATE AMENDMENT HISTORY 1.0 2013 Previous version 2.0 September 2015 Comments Amendment to Flow chart and addition of Rationale page
More informationMANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) Routine endoscopic investigation of patients of any age, presenting with dyspepsia
More information2018 CONSENSUS UPDATES + RISKS/BENEFITS OF PPI USE
2018 CONSENSUS UPDATES + RISKS/BENEFITS OF PPI USE IN INFANT GERD SWEDISH MEDICAL CENTER JONAH ESSERS, MD, MPH OBJECTIVES Highlight the 2018 updates to infant GERD recommendations Provide an update on
More informationManagement of Dyspepsia
MPharm Programme Management of Dyspepsia Slide 1 of 28 Learning Objectives Understand the principles and wider implications underpinning evidence based therapeutics in the key clinical specialities Objectively
More informationPerplexed by PPI s Should I be Worried? James R Gray Gastroenterology Vancouver
Perplexed by PPI s Should I be Worried? James R Gray Gastroenterology Vancouver Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted
More informationGastro esophageal reflux disease DR. AMMAR I. ABDUL-LATIF
Gastro esophageal reflux disease )GERD( DR. AMMAR I. ABDUL-LATIF GERD DEFINITION EPIDEMIOLOGY CAUSES PATHOGENESIS SIGNS &SYMPTOMS COMPLICATIONS DIAGNOSIS TREATMENT Definition Montreal consensus defined
More informationPractical Guide to Safety of PPIs What to Tell Your Patient. Proton Pump Inhibitors
Practical Guide to Safety of PPIs What to Tell Your Patient Joel E Richter, MD, FACP, MACG Professor and Director Division of Digestive Diseases and Nutrition Joy Culverhouse Center for Esophageal Diseases
More informationCOMPUS OPTIMAL THERAPY REPORT. Supporting Informed Decisions. À l appui des décisions éclairées
OPTIMAL THERAPY REPORT COMPUS Volume 1, Issue 5 March 2007 Current Practice Analysis Report for the Prescribing and Use of Proton Pump Inhibitors (PPIs) Supporting Informed Decisions À l appui des décisions
More informationNexium 24HR. Tools and information for you and your pharmacy team NOW OTC FOR FREQUENT HEARTBURN. Consumer Healthcare Pfizer Inc.
NOW OTC FOR FREQUENT HEARTBURN w e N Nexium 24HR P H A R M A S S I S T K I T Tools and information for you and your pharmacy team 2014 Pfizer Inc. NXM041468 05/14 Q: What is the indication for Nexium 24HR
More informationLONG -TERM USE OF PPIS: INDICATIONS, BENEFITS AND HARMS. Jihane Naous, M.D.
LONG -TERM USE OF PPIS: INDICATIONS, BENEFITS AND HARMS Jihane Naous, M.D. Objectives Identify the conditions supported by AGA/ACG guidelines necessitating long-term use of daily PPIs, Recognize which
More informationGastroesophageal Reflux Disease (GERD)
Gastroesophageal Reflux Disease (GERD) Information for patients UHN Read this handout to learn about: What gastroesohageal reflux (GERD) is Signs and symptoms How your doctor will know if you have it Tests
More informationRpts. GENERAL General Schedule (Code GE)
Pantoprazole 20mg Name, Restriction, Manner of administration and form Pantoprazole 20mg enteric tablet, 30 (8399C) Gastro-oesophageal reflux disease Name, Restriction, Manner of administration and form
More informationHoward K. Gogel, MD Southwest Gastroenterology Associates November 2017
Howard K. Gogel, MD Southwest Gastroenterology Associates November 2017 PPI indications and Overuse of PPIs Association vs causation (relative risk, odds ratios) Problems: Hypergastrinemia: ECL hyperplasia,
More informationPage 1 of 5 Official reprint from UpToDate www.uptodate.com 2017 UpToDate Patient education: Acid reflux (gastroesophageal reflux disease) in adults (The Basics) Written by the doctors and editors at UpToDate
More informationOVERALL SUMMARY OF THE SCIENTIFIC EVALUATION OF LOSEC AND ASSOCIATED NAMES (SEE ANNEX I)
ANNEX II SCIENTIFIC CONCLUSIONS AND GROUNDS FOR AMENDMENT OF THE SUMMARY OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET PRESENTED BY THE EMEA 21 SCIENTIFIC CONCLUSIONS OVERALL SUMMARY OF THE
More informationACG Clinical Guideline: Diagnosis and Management of Gastroesophageal Reflux Disease
ACG Clinical Guideline: Diagnosis and Management of Gastroesophageal Reflux Disease Philip O. Katz MD 1, Lauren B. Gerson MD, MSc 2 and Marcelo F. Vela MD, MSCR 3 1 Division of Gastroenterology, Einstein
More informationCOMPUS OPTIMAL THERAPY REPORT. Supporting Informed Decisions. À l appui des décisions éclairées
OPTIMAL THERAPY REPORT COMPUS Volume 1, Issue 6 March 2007 Gap Analysis Report for the Prescribing and Use of Proton Pump Inhibitors (PPIs) Supporting Informed Decisions À l appui des décisions éclairées
More informationCommittee Approval Date: October 14, 2014 Next Review Date: October 2015
Medication Policy Manual Topic: esomeprazole-containing medications: - Nexium - Vimovo - esomeprazole strontium Policy No: dru039 Date of Origin: May 2001 Committee Approval Date: October 14, 2014 Next
More informationCYP2C19-Proton Pump Inhibitors
CYP2C19-Proton Pump Inhibitors Cameron Thomas, Pharm.D. PGY2 Clinical Pharmacogenetics Resident St. Jude Children s Research Hospital February 1, 2018 Objectives: CYP2C19-PPI Implementation Review the
More informationSASKATCHEWAN REGISTERED NURSES ASSOCIATION
DEFINITION Reflux of gastric contents into the esophagus, which results in esophageal irritation or inflammation. IMMEDIATE CONSULTATION REQUIRED IN THE FOLLOWING SITUATIONS Dysphagia (solid food, progressive)
More informationAll Indiana Medicaid Prescribers and Pharmacy Providers
P R O V I D E R B U L L E T I N BT200148 NOVEMBER 28, 2001 To: All Indiana Medicaid Prescribers and Pharmacy Providers Subject: Note: The information in this bulletin regarding prior authorization payment
More information11/19/2012. Comparison between PPIs G CELL. Risk ratio (95% CI) Patient subgroup. gastrin. S-form of omeprazole. Acid sensitive. coated.
REGULATION OF GASTRIC ACID SECRETION Comparison between PPIs Omeprazole Lansoprazole Rabeprazole Pantoprazole Esomeprazole gastrin G CELL + Acid sensitive Yes T1/2 30-60 minutes Main elimination Enteric
More informationOptimal Management of GERD with Dexlansoprazole - Extended plasma concentration and dosing flexibility with a dual delayed release PPI
Optimal Management of GERD with Dexlansoprazole - Extended plasma concentration and dosing flexibility with a dual delayed release PPI Jun Heng Lee, M.D. Samsung Medical Center, Sungkyunkwan University
More informationProton Pump Inhibitors- Questions & Controversies. Farah Kablaoui, PharmD, BCPS, BCCCP
Proton Pump Inhibitors- Questions & Controversies Farah Kablaoui, PharmD, BCPS, BCCCP Disclosure Information Proton Pump Inhibitors: Questions & Controversies Farah Kablaoui I have no financial relationship
More informationBleeding Prevention in an Era of Expanding Combination Antithrombotic Therapies
Bleeding Prevention in an Era of Expanding Combination Antithrombotic Therapies Muthiah Vaduganathan, MD MPH Cardiovascular Medicine Brigham and Women s Hospital December 8 th, 2017 Disclosures None Key
More informationBurning Issues in Gastroesophageal Reflux Disease (GERD)
3:45 4:45pm Burning Issues in GERD SPEAKER Prateek Sharma, MD, FACG, FACP Presenter Disclosure Information The following relationships exist related to this presentation: Prateek Sharma, MD, FACG, FACP,
More informationPROTON PUMP INHIBITOR AND CLOPIDOGREL INTERACTION: Am J Gastroenterol Jan;105(1): Epub 2009 Nov 10.
PROTON PUMP INHIBITOR AND CLOPIDOGREL INTERACTION: FACT OR FICTION? 本檔僅供內部教學使用檔案內所使用之照片之版權仍屬於原期刊公開使用時, 須獲得原期刊之同意授權 Am J Gastroenterol. 2010 Jan;105(1):34-41. Epub 2009 Nov 10. Introduction Current consensus
More informationMY PATIENT HAS READ THAT HIS PPI S MAY BE TROUBLE. NOW WHAT?
MY PATIENT HAS READ THAT HIS PPI S MAY BE TROUBLE. NOW WHAT? Clarence Wong MD FRCPC Associate Professor FACULTY/PRESENTER DISCLOSURE Faculty: Clarence Wong Relationships with commercial interests: Grants/Research
More informationPLANNING COMMITTEE. Seek simplicity, and mistrust it. Alfred North Whitehead
PLANNING COMMITTEE 1. Content Experts Clinical experts Desmond Leddin MB FRCPC, Head, Division of Gastroenterology, Dalhousie University Drug evaluation pharmacist Pam McLean-Veysey BScPharm, Drug Evaluation
More informationGERD: Pitfalls and Pearls
GERD: Pitfalls and Pearls Gary W. Falk, M.D., M.S. Professor of Medicine Division of Gastroenterology Perelman School of Medicine of the University of Pennsylvania Conflicts of Interest Nothing to disclose
More informationAN ARGUMENT FOR SURGERY FOR GASTRINOMA. Lauren Wilson R1 General Surgery
AN ARGUMENT FOR SURGERY FOR GASTRINOMA Lauren Wilson R1 General Surgery WHAT IS A GASTRINOMA? Gastrin secreting cells derived from multipotential stem cells of endodermal origin or enteroendocrine cells
More informationJuly 19, Division of Dockets Management Food and Drug Administration 5630 Fishers Lane Room 1061, HFA-305 Rockville, Maryland 20852
July 19, 2017 Division of Dockets Management Food and Drug Administration 5630 Fishers Lane Room 1061, HFA-305 Rockville, Maryland 20852 Re: Comments on Citizen s Petition #FDA-2017-P-2733 Herein, the
More informationNEGATIVE ENDOSCOPY, What is the Diagnosis and Treatment?
NEGATIVE ENDOSCOPY, PPI REFRACTORY REFLUX: What is the Diagnosis and Treatment? Michael F. Vaezi, MD, PhD, MSc, FACG Professor of Medicine Clinical Director Division of Gastroenterology, Hepatology and
More informationSpeaker disclosure. Objectives. GERD: Who and When to Treat 7/21/2015
GERD: Who and When to Treat Eugenio J Hernandez, MD Gastrohealth, PL Assistant Professor of Clinical Medicine, FIU Herbert Wertheim School of Medicine Speaker disclosure I do not have any relevant commercial
More informationNexium 24HR Pharmacy Training
Nexium 24HR Pharmacy Training Your pharmacist's advice is required. Always read the label. Use only as directed. If symptoms persist, consult your doctor/ healthcare professional. Pfizer Consumer Healthcare
More informationAGA SECTION. Gastroenterology 2016;150:
Gastroenterology 2016;150:1026 1030 April 2016 AGA Section 1027 Procedural intervention (3) Upper endoscopy indications 3 6 Non-response of symptoms to a 4 8 week empiric trial of twice-daily PPI Troublesome
More informationTEXAS VENDOR DRUG PROGRAM
1 OF 12 Publication History o Revised March 2015; June 2013; November 2011; September 2011; September 20009; June 2009; December 2005; November 2003; October 2002. o Developed December 2001. Prepared by
More informationGastroesophageal Reflux Disease, Paraesophageal Hernias &
530.81 553.3 & 530.00 43289, 43659 1043432842, MD Assistant Clinical Professor of Surgery, UH JABSOM Associate General Surgery Program Director Director of Minimally Invasive & Bariatric Surgery Programs
More informationGERD, peptic ulcer disease, and celiac disease: updates from the upper GI tract
GERD, peptic ulcer disease, and celiac disease: updates from the upper GI tract Primary Care Internal Medicine, October 15, 2018 Kyle Staller, MD, MPH Director, Gastrointestinal Motility Laboratory Center
More informationGuidelines for the Management of Dyspepsia and GORD. Gastroenterology/ Acute Adult Governance. Drugs and Therapeutics Committee
Guidelines for the Management of Dyspepsia and GORD Document type: Version: 3.0 Author (name): Author (designation): Validated by Prescribing Dr. G. Lipscomb Date validated October 2015 Ratified by: Date
More informationPatient advice regarding long term use of Proton Pump Inhibitors (PPIs)
Patient advice regarding long term use of Proton Pump Inhibitors (PPIs) Information for you Follow us on Twitter @NHSaaa Find us on Facebook at www.facebook.com/nhsaaa Visit our website: www.nhsaaa.net
More informationGastroesophageal Reflux Disease (GERD)
Gastroesophageal Reflux Disease (GERD) Acid Reflux Acid reflux occurs when acid from the stomach moves backwards into the esophagus. Heartburn Heartburn is a symptom of acid reflux and GERD. It may feel
More informationUnmet Needs in the Management of Gastroesophageal Reflux Disease
Unmet Needs in the Management of Gastroesophageal Reflux Disease Ronnie Fass MD Professor of Medicine Case Western Reserve University Chairman, Division of Gastroenterology and Hepatology Director, Esophageal
More informationNational Digestive Diseases Information Clearinghouse
Gastritis National Digestive Diseases Information Clearinghouse U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH What is gastritis? Gastritis is a condition in which the stomach
More informationGastro-oesophageal reflux disease and peptic ulcer disease. By: Dr. Singanamala Suman Assistant Professor Department of Pharm.D
Gastro-oesophageal reflux disease and peptic ulcer disease By: Dr. Singanamala Suman Assistant Professor Department of Pharm.D Gastro-oesophageal reflux disease and peptic ulcer disease Learning objectives:
More informationGERD. From Clinician to Pharmacologist. Chien-Heng, Shen
GERD From Clinician to Pharmacologist Chien-Heng, Shen 2014.9.24 Gastroesophageal Reflux Disease (GERD) when the reflux of gastric content causes troublesome symptoms or complications Esophageal Syndromes
More informationH o w d o e a c t. y o u r a c i
H o w d o e a c t p a n t o p r a b r e a k d y o u r a c i Pantoprazole Sodium is the sodium salt form of a substituted benzimidazole with proton pump inhibitor activity. Pantoprazole is a lipophilic,
More informationGERD: A linical Clinical Clinical Update Objectives
GERD: A Clinical Update Jeff Gilbert, M.D. University i of Kentucky Gastroenterology 11/6/08 Objectives To review the basic pathophysiology underlying gastroesophageal reflux disease To highlight current
More informationReflux of gastric contents, particularly acid, into the esophagus
Heartburn Reflux of gastric contents, particularly acid, into the esophagus Patient assessment with GERD 1-signs and symptoms The hallmark of typical symptom of GERD is heartburn (restrosternal),acid regurgitation,
More informationS. Sandberg-Lewis, ND, DHANP
Functional Gastroenterology Webinar One 6-28-13 S. Sandberg-Lewis, ND, DHANP Proton pump inhibitors- Effects on: secretion gastric mucosa food allergy bile reflux Barrett metaplasia and dysplasia esophageal
More informationCopy right protected Page 1
DRUGS USED IN ULCERS AND GIT DISORDERS A peptic ulcer, also known as PUD or peptic ulcer disease is an ulcer of an area of the gastrointestinal tract that is usually acidic and thus extremely painful.
More informationPhiladelphia College of Osteopathic Medicine. Shawn P. Mahoney Philadelphia College of Osteopathic Medicine,
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2011 Is Esomeprazole (Nexium) More Effective
More informationRisk of GI Bleeding and Use of PPIs
Risk of GI Bleeding and Use of PPIs ESC 211 August 28, 211 Marc S. Sabatine, MD, MPH Chairman, TIMI Study Group Associate Physician, Cardiovascular Division, BWH Associate Professor of Medicine, Harvard
More informationOral proton pump inhibitors (PPIs)
Treatment Guideline Oral proton pump inhibitors (PPIs) Introduction The high efficacy and low toxicity of proton pump inhibitors (PPIs) has contributed to their frequent prescription worldwide, often without
More informationThe Clinical Debates
The Clinical Debates ACPE UAN 0107-0000-10-029-L01-P & 0107-0000-10-029-L01-T Activity Type: Application-Based 0.1 CEUs/1.0 Hr. Program Objectives for Pharmacists: Upon completion of this program, participants
More informationTBURN TBURN BURN ARTBURN EARTBURN EART HEARTBURN: HOW TO GET IT OFF YOUR CHEST
TBURN BURN TBURN ARTBURN. EARTBURN EART N EARTBURN HEARTBURN: HOW TO GET IT OFF YOUR CHEST Do you sometimes wake up at night with a sharp, burning sensation in your chest? Does this sometimes happen during
More informationCan you take digestive enzymes while
Can you take digestive enzymes while taking PPIs Feb 14, 2011. This can occur during treatment with acid-blocking medications or as. Thus, if you are taking digestive enzymes to accelerate the emptying
More informationDifference between omeprazole and omeprazole delayed release
Cari untuk: Cari Cari Difference between omeprazole and omeprazole delayed release 7-2-2018 Easy to read patient leaflet for Omeprazole Delayed-Release Capsules. Includes indications, proper use, special
More informationhttps://www.uptodate.com/contents/acid-reflux-gastroesophageal-reflux-disease-in-adults-...
Page 1 of 10 Official reprint from UpToDate www.uptodate.com 2017 UpToDate The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.
More informationSafety Of. long-term PPI. Layli Eslami, MD Tehran, 1393
Safety Of long-term PPI Layli Eslami, MD Tehran, 1393 n The introduction of PPIs in the late 1980s optimized the medical treatment of acidrelated disorders n In some cases such as GERD patients given the
More informationFARMACI E ALTE VIE DIGESTIVE NELL ANZIANO: UTILITÀ E LIMITI
FARMACI E ALTE VIE DIGESTIVE NELL ANZIANO: UTILITÀ E LIMITI Edoardo V. Savarino, MD, PhD Professor of Gastroenterology Department of Surgery, Oncology and Gastroenterology University of Padua Italy COMMON
More informationClass Update: Proton Pump Inhibitors and Histamine 2 Receptor Antagonists
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More information1. The proposed strength, quantity, dosage form, dose and route of administration of the medicine including indication
Investigation 10mg 1. The proposed strength, quantity, dosage form, dose and route of administration of the medicine including indication Blister packs of 14 Solid dose form for oral administration. It
More informationProton pump inhibitors: balancing the benefits and risks of long-term use
Proton pump inhibitors: balancing the benefits and risks of long-term use Chenlu (Maria) Tian, MD Assistant Professor Digestive and Liver Disease University of Texas Southwestern Medical Center This is
More informationlong term use Nexium Nexium
NEXIUM 40 mg Tablets - Summary of Product Characteristics (SPC) by AstraZeneca Pharmaceuticals (Ireland) DAC. Nexium 20mg, 40mg Tablets - Patient Information Leaflet (PIL) by AstraZeneca UK Limited. Information
More informationKK College of Nursing Peptic Ulcer Badil D ass Dass, Lecturer 25th July, 2011
KK College of Nursing Peptic Ulcer Badil Dass, Lecturer 25 th July, 2011 Objectives: By the end of this lecture, the students t will be able to: Define peptic pp ulcer Describe the etiology and pathology
More informationIs Rabeprazole A Safe Treatment for Gastroesophageal Reflux Disease in Children Ages 1-16 years?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2015 Is Rabeprazole A Safe Treatment for Gastroesophageal
More informationTreatment Options for GERD or Acid Reflux Disease A Review of the Research for Adults
Treatment Options for GERD or Acid Reflux Disease A Review of the Research for Adults hur till återvinna från prostataoperation Is This Information Right for Me? Yes, if: A doctor said that you have gastroesophageal
More informationComplications of Proton Pump Inhibitor Therapy. Gastroenterology 2017; 153:35-48 발표자 ; F1 김선화
Complications of Proton Pump Inhibitor Therapy Gastroenterology 2017; 153:35-48 발표자 ; F1 김선화 Background Proton pump inhibitors (PPIs) are among the most commonly prescribed medicines for gastroesophageal
More informationProton Pump Inhibitor Clinical Trials: Focus On Lansoprazole In The Treatment Of Gastroesophageal Reflux Disease And Frequent Heartburn
ISPUB.COM The Internet Journal of Advanced Nursing Practice Volume 11 Number 1 Proton Pump Inhibitor Clinical Trials: Focus On Lansoprazole In The Treatment Of Gastroesophageal J Pallentino Citation J
More informationAntiplatelets in cardiac patients with suspected GI bleeding
Antiplatelets in cardiac patients with suspected GI bleeding Acute GI bleeding is a common major medical emergency. In the 2007 UK-wide audit, overall mortality of patients admitted with acute GI bleeding
More informationZantac for stomach ulcers
P ford residence southampton, ny Zantac for stomach ulcers Information on the drug ranitidine (Zantac) used in and duodenal ulcers, heartburn, esophagitis, and Zollinger Ellison Syndrome. Side. But with
More informationHigh use of maintenance therapy after triple therapy regimes in Ireland
High use of maintenance therapy after triple therapy regimes in Ireland K Bennett, H O Connor, M Barry, C O Morain, J Feely Department of Pharmacology & Therapeutics Department of Gastroenterology Trinity
More informationGI Pharmacology. Dr. Alia Shatanawi 5/4/2018
GI Pharmacology Dr. Alia Shatanawi 5/4/2018 Drugs Used in Gastrointestinal Diseases Drugs used in Peptic Ulcer Diseases. Drugs Stimulating Gastrointestinal Motility &Laxatives. Antidiarrheal Agents. Drugs
More informationFast Facts In OTC PPI s
Page 1 Fast Facts in OTC PPI s Fast Facts in OTC PPIs James M. Scheiman, MD Professor of Internal Medicine Division of Gastroenterology University of Michigan Medical School Ann Arbor, Michigan This program
More information